NCT06130722 - First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

May 15, 2026

Study Completion Date

September 30, 2026

Conditions

Locally Advanced/Metastatic Solid Tumors

Interventions

DRUG

FL115

FL115 is a novel long-acting IL-15 agonist designed as a fusion protein with a mutated IL-15 structure (IL-15\[N72D\]/IL-15Rα-sFc).

Trial Locations (3)

RECRUITING

Gabriel Cancer Center, Canton

RECRUITING

Moores Cancer Center at UCSD Health, San Diego

RECRUITING

HOAG Memorial Hospital Presbyterian, Newport Beach

All Listed Sponsors

lead

Suzhou Forlong Biotechnology Co.,Ltd,

INDUSTRY